Events
5 minute read

The Shifting Landscape of Bio/Pharma Litigation: The Influence of PTAB Proceedings (Live MBHB Webinar)

Alison J. BaldwinPaula S. Fritsch, Ph.D.September 20, 201610:00 am - 11:15 amLive MBHB Webinar via WebEx

Tues., Sept. 20, 2016 | 10:00-11:15 a.m. CT | Live MBHB Webinar via WebEx


The invalidity proceedings before the Patent Trial and Appeal Board (PTAB) created by the America Invents Act had an almost immediate impact on litigation defense strategies in the financial services and technology fields. The impact in the bio/pharma field was slower, but has steadily increased. Even the highly regulated areas of ANDA and biosimilar patent litigation are being impacted by the more routine use of these PTAB invalidity proceedings.


Join us as we discuss the following topics:




  • A look at who is using PTAB proceedings to challenge bio/pharma patents;


  • A review of how bio/pharma patents have fared before the PTAB, since inception and more recently;


  • An analysis of how PTAB proceedings are impacting ANDA and biosimilar litigations; and


  • A discussion of the potential future impact of PTAB invalidity proceedings in the bio/pharma space.

 


Presenter(s): MBHB partners Alison Baldwin and Paula Fritsch, Ph.D.


 


Access an archived audio version of this webinar here.


NOTE: MCLE credit is not available for this archived recording.


McDonnell Boehnen Hulbert & Berghoff LLP is committed to educating clients and friends of the firm with respect to significant developments and trends in the areas of intellectual property law.